Estrogen and Progesterone Receptors in breast cancer – IHC reporting – GUIDELINES
Publishing Authority: American Society of Clinical Oncology / College of American Pathologists (ASCO / CAP)
Recommendation:
- POSITIVE – ≧1% of tumor cell nuclei are immunoreactive
- NEGATIVE – < 1% of tumor cell nuclei are immunoreactive (positive intrinsic controls are present)
- UNINTERPRETABLE – no tumor nuclei are immunoreactive and that internal controls present in the sample or separately submitted from the same sample lack any nuclear staining
Reference:
1. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. 2010;134:907–922. Pathref accessibility score 4.
2. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol. 2010;28(16):2784-95. Pathref accessibility score 4.
History:
1. The ASCO Clinical Practice Guidelines Committee (CPGC) and the CAP Council on Scientific Affairs (CSA) jointly convened an Expert Panel in 2008 to form guidelines.
2. Simultaneously published in Journal of Clinical Oncology and Archives of Pathology & Laboratory Medicine in 2010.